Evaluation of the spectrum of genetic variations in young cancer patients presenting to the tertiary cancer centre

Background: Aim of the study was to evaluate spectrum genetic variations in young cancer patients presenting tertiary center Methods: All newly diagnosed with medical oncology OPD at continental hospitals between November 2021 till July 2023 were analyzed. Multigene panel testing (56 genes) by next-generation sequencing performed for all patients. Demographics and clinical characters represented using descriptive statistics. The Chi-square test used compare cohorts Mutations vs. non mutations. Results: A total 130 screened 70 recruited study, which had complete set details available. Median age Cohort is 41.9±6.6 years females it 43.6±6.8 males 40.5±7.3, approximately 3 earlier than (p=0.12), not statistically significant. Male female ratio 1.2:1, much less compared Globocon statistics India. 47% (33/70) subjects some mutation 16% (11/70) variance unknown significance 32% (22/70) pathogenic variants. commonest breast followed colon prostate. Conclusions: Younger atypical symptoms harbor more frequent germ line mutations, expected. In view low cost, standardized wide availability analysis, it’s preferred offer test, wherever clinically relevant. This can help better education, screening early intervention, that ultimately improve healthier directions.